{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-118322","form_type":"8-K","ticker":"XOMA","cik":"0000791908","company_name":"XOMA Royalty Corp","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.285057+00:00","generated_at":"2026-05-21T19:27:57.978773+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"XOMA Royalty Q1 net income $2.4M, total revenues $15.9M; adds Castle Creek royalty, sells Kinnate assets","bullets":["Q1 2025 total revenues $15.9M (vs $1.5M Q1 2024); net income $2.4M (vs net loss $8.6M).","Cash receipts $18.0M in Q1, including $13.4M royalties and $4.6M milestones; cash $95.0M at March 31.","Acquired Phase 3 royalty interest in Castle Creek's D-Fi (DEB) for $5M; sold all unpartnered Kinnate assets.","Milestone: $4.0M from Day One/Ipsen MAA filing for tovorafenib with EMA; $3.0M net from Takeda Phase 3 start (Q2).","Share repurchases: $0.5M for 25,828 shares; paid $1.4M in preferred dividends."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-118322","json":"https://secwatch.observer/filing/0001193125-25-118322.json","markdown":"https://secwatch.observer/filing/0001193125-25-118322.md","text":"https://secwatch.observer/filing/0001193125-25-118322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/791908/000119312525118322/0001193125-25-118322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/791908/000119312525118322/d905797d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T19:27:57.978773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}